Bind teams up with Pfizer for its Accurins
Executive Summary
Targeted drug developer Bind Therapeutics Inc. (recently changed its name from Bind Biosciences) has licensed Pfizer Inc. the exclusive worldwide option to develop and commercialize Accurin candidates chosen by the Big Pharma.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice